US pharmacy pricing
Tabrecta Prices at US Pharmacies
Lowest price found · US pharmacies
$22,821.61/fill
for Tabrecta, across the pharmacies in our data
US pharmacy prices — 200mg
| Pharmacy | Discount-card price | Regular cash price | Average retail |
|---|---|---|---|
| $22,821.61Lowest | $22,824.61 | $6.50 | |
| $22,821.61Lowest | $22,824.61 | $6.50 | |
| $23,807.59 | $23,807.59 | $6.50 | |
| $23,943.34 | $23,946.34 | $6.50 | |
| $24,084.59 | $24,087.59 | $6.50 | |
| $24,641.58 | $24,644.58 | $6.50 |
"Discount-card price" reflects a standard prescription discount card, not insurance. Prices change often — confirm at the pharmacy before filling.
Interchangeable forms
Per RxNorm (U.S. National Library of Medicine), these share the same active ingredient and strength as Tabrecta.
Frequently asked questions
How much does Tabrecta (Tabrecta) cost without insurance?
Our most recent US pharmacy data shows a low of roughly $22,821.61 for Tabrecta with a standard discount card. That figure moves with dosage and quantity — check the comparison table for the exact combination you need.
Does Tabrecta have a generic equivalent?
Generic and brand-name pricing for Tabrecta is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.
How is the cost of Tabrecta determined for patients with insurance?
Coverage and cost for Tabrecta under insurance plans, including Medicare and Medicaid, vary significantly based on the specific formulary and benefit structure. The out-of-pocket copay or coinsurance amount can differ from one plan to another. To determine your exact cost, it is best to contact your insurance provider or pharmacist. If your plan does not cover Tabrecta, or if the copay is high, exploring alternative savings options such as manufacturer patient assistance programs or pharmacy discount cards may be beneficial.
Can I get a generic version of Tabrecta?
No. Tabrecta is the brand-name version of the drug capmatinib, developed by Novartis. A generic equivalent is not currently available on the market.